文献速递胸部肿瘤支持与姑息治疗

阿司匹林、他汀与二甲双胍和肺癌风险及死亡率的关联:全国代表性人群的时依分析

The Associations of Aspirin, Statins, and Metformin With Lung Cancer Risk and Related Mortality: A Time-Dependent Analysis of Population-Based Nationally Representative Data.
PubMed 文献 · J Thorac Oncol · 2020-09-17

该研究基于韩国732199名2002-2003年参加国家健康体检者,随访至2013年,采用时依Cox分析避免永恒时间偏倚,评估阿司匹林、二甲双胍、他汀累积使用与肺癌发病和死亡的关系。结果显示二甲双胍使用与肺癌发病和死亡呈剂量反应性保护关联,阿司匹林和他汀与肺癌死亡率呈剂量依赖性降低关联,三药联合保护关联更明显。

要点

  • 二甲双胍累积使用与肺癌发病及死亡风险呈剂量反应性降低关联。
  • 阿司匹林和他汀使用与肺癌死亡率呈剂量依赖性降低关联。
  • 阿司匹林、他汀和二甲双胍联合使用与肺癌风险和死亡的保护关联更明显。

核心结论

  • 阿司匹林、二甲双胍和他汀的使用与肺癌死亡率有独立保护关联,二甲双胍与肺癌风险呈负关联。

主要发现

  • 二甲双胍使用与肺癌发病(趋势P=0.008)和死亡(趋势P<0.001)呈剂量反应性保护关联,在累积定义日剂量≥547.5的参与者中较无糖尿病者更明显。
  • 阿司匹林使用与肺癌死亡率呈剂量依赖性降低(趋势P=0.046),他汀使用与肺癌死亡率呈剂量依赖性降低(趋势P<0.001)。
  • 阿司匹林、他汀和二甲双胍联合使用与肺癌风险和死亡的保护关联更明显。

临床怎么用

  • 在肺癌高危人群中,应关注二甲双胍、阿司匹林和他汀的使用史及其累积剂量,作为风险分层和随访的参考信息。
  • 对于合并糖尿病需用二甲双胍、或需用阿司匹林/他汀的患者,可向患者说明这些药物与肺癌死亡风险降低的关联,但不应改变肺癌标准治疗。
  • 三药联合使用与更强的保护关联提示未来可能作为肺癌化学预防策略的研究方向,但目前尚不能用于临床推荐。

局限性

  • 研究为观察性设计,药物暴露基于处方记录,可能存在适应证混杂和残余混杂。
  • 研究人群为韩国全国健康体检参与者,结果外推到其他人群需谨慎。
  • 药物暴露定义基于累积使用时长和累积定义日剂量,未区分不同他汀或阿司匹林剂量。
  • 随访期间未动态纳入新发合并症或生活方式变化,可能影响关联估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The aim of this study was to investigate the associations of aspirin, metformin, and statins with lung cancer risk and mortality using population-based nationwide cohort data. METHODS: This study included a total of 732,199 participants who underwent a national health check-up from 2002 to 2003. Lung cancer incidence and mortality were identified using a registered lung cancer diagnosis code (International Classification of Diseases, 10th revision, code C34) and the Korean National Death Registry. The study participants were followed up from January 1, 2004 to December 31, 2013. Medication exposure was defined by the cumulative duration of use and cumulative defined daily dose per 2-year interval. To avoid immortal-time bias, drug exposure was inserted as a time-dependent variable in Cox analysis, which evaluated the associations of these medications with lung cancer. RESULTS: Metformin use had a protective association with lung cancer incidence (p's for trend 0.008) and mortality (p's for trend < 0.001) in a dose-response fashion, and these associations were prominent among participants with a metformin cumulative defined daily dose of 547.5 and above compared with patients without diabetes. Lung cancer mortality was dose-dependently reduced with the use of aspirin (p's for trends 0.046) and statin (p's for trends < 0.001). The combined use of aspirin, statins, and metformin exhibited more prominent protective associations with lung cancer risk and mortality. CONCLUSIONS: The use of aspirin, metformin, and statins had independent protective associations with lung cancer mortality, and metformin had an inverse association with lung cancer risk. Further studies are necessary to develop clinically applicable anticancer strategies using these drugs for the reduction of lung cancer and related mortality.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Kang J, Jeong SM, Shin DW, et al. The Associations of Aspirin, Statins, and Metformin With Lung Cancer Risk and Related Mortality: A Time-Dependent Analysis of Population-Based Nationally Representative Data. J Thorac Oncol. 2020. PMID: 32950701. doi:10.1016/j.jtho.2020.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。